PharVision Advisers’s Leidos LDOS Stock Holding History

PharVision Advisers’s Portfolio LDOS Stock Details LDOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,759	Closed	-$372K	–	362
2025 Q1	$372K	Buy	+2,759	New	+$385K	0.52%	55

Other funds holding LDOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's LDOS Position: Q2 2025 in Review

PharVision Advisers sold out of Leidos (LDOS) in Q2 2025, closing a stake of 2,759 shares — an estimated $372K sold.

PharVision Advisers first reported a position in LDOS in Q1 2025 and held it in 1 quarter. The position peaked at $372K in Q1 2025. 827 funds tracked by Wall St. Rank hold LDOS as of Q2 2025.

PharVision Advisers reported no remaining Leidos position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 2,759 Leidos shares in Q2 2025, an estimated $372K.
PharVision Advisers first reported a position in Leidos in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Leidos position peaked at $372K in Q1 2025.
827 funds tracked by Wall St. Rank held Leidos as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.